Longitudinal Optic Neuritis Study (LONS)
Launched by NATIONAL EYE INSTITUTE (NEI) · Sep 23, 1999
Trial Information
Current as of January 15, 2025
Unknown status
Keywords
ClinConnect Summary
Optic neuritis is an inflammatory disease of the optic nerve that typically affects young adults. Women are affected more often than men. It is second only to glaucoma as the most common acquired optic nerve disorder in persons younger than age 50.
In this disorder, closely linked to multiple sclerosis, prognosis for visual recovery is generally good. However, return of visual function is almost never complete. After resolution of optic neuritis, virtually all patients show some signs of optic nerve damage, and most are symptomatic. Even when a patient's acuity recovers to 20/20, abnormali...
Gender
ALL
Eligibility criteria
- The major eligibility criteria for enrollment into the ONTT included the following:
- • Age range of 18 to 46 years
- • Acute unilateral optic neuritis with visual symptoms for 8 days or less
- • A relative afferent pupillary defect and a visual field defect in the affected eye
- • No previous episodes of optic neuritis in the affected eye
- • No previous corticosteroid treatment for optic neuritis or multiple sclerosis
- • No systemic disease other than multiple sclerosis that might be the cause of the optic neuritis
About National Eye Institute (Nei)
The National Eye Institute (NEI), part of the U.S. National Institutes of Health (NIH), is dedicated to conducting and supporting innovative research to understand, prevent, and treat eye diseases and vision disorders. As a leading sponsor of clinical trials, NEI aims to advance knowledge in ocular health through rigorous scientific inquiry and collaboration with researchers, healthcare professionals, and institutions. By fostering the development of new therapies and technologies, NEI plays a pivotal role in enhancing the quality of life for individuals affected by visual impairments and eye conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Little Rock, Arkansas, United States
San Francisco, California, United States
Washington, District Of Columbia, United States
Gainesville, Florida, United States
Chicago, Illinois, United States
Iowa City, Iowa, United States
Baltimore, Maryland, United States
Ann Arbor, Michigan, United States
East Lansing, Michigan, United States
New York, New York, United States
Durham, North Carolina, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Houston, Texas, United States
Seattle, Washington, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials